Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clascoterone + benzoyl peroxide is a topical combination therapy used in the treatment of acne vulgaris. Clascoterone is an androgen receptor inhibitor that acts locally in the skin to block dihydrotestosterone (DHT) from binding to androgen receptors in sebaceous glands and hair follicles, thereby reducing sebum production and inflammation. Benzoyl peroxide is an antimicrobial agent with keratolytic properties that reduces *Cutibacterium acnes* colonization and helps prevent follicular plugging. The combination targets multiple pathogenic factors of acne—hormonal stimulation of sebum production and bacterial proliferation/inflammation—making it a rational multimodal approach for moderate-to-severe acne vulgaris[3][4][6][8]. Clinical studies have shown that using these agents together can be effective and generally well tolerated, though concurrent application may increase local irritation such as redness or dryness[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clascoterone + benzoyl peroxide.